Comparative Pharmacology
Head-to-head clinical analysis: BROMPHENIRAMINE MALEATE versus CETIRIZINE HYDROCHLORIDE ALLERGY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROMPHENIRAMINE MALEATE versus CETIRIZINE HYDROCHLORIDE ALLERGY.
BROMPHENIRAMINE MALEATE vs CETIRIZINE HYDROCHLORIDE ALLERGY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of histamine at H1 receptor sites, suppressing histamine-induced vasodilation, increased capillary permeability, and bronchoconstriction.
Cetirizine hydrochloride is a second-generation histamine H1-receptor antagonist. It acts by selectively and reversibly blocking histamine H1 receptors on effector cells (e.g., smooth muscle, endothelial cells, mucous glands), thereby inhibiting histamine-mediated allergic responses such as vasodilation, increased vascular permeability, bronchoconstriction, and itching. It does not prevent histamine release but antagonizes its effects.
4 mg orally every 4-6 hours, not to exceed 24 mg/day. Alternatively, extended-release: 12 mg every 12 hours.
5-10 mg orally once daily; maximum 10 mg/day.
None Documented
None Documented
Terminal half-life 22-25 hours; prolonged in hepatic impairment or elderly (up to 40 hours).
Terminal elimination half-life: approximately 8-11 hours in healthy adults; increases to ~18-20 hours in elderly (due to decreased renal function); prolonged in renal impairment (CrCl <31 mL/min: up to 20-30 hours)
Renal (85-90% as metabolites, 5-10% unchanged); biliary/fecal <5%.
Renal: approximately 70% (60% as unchanged drug, 10% as metabolites); Fecal: approximately 10%; Biliary: negligible
Category C
Category A/B
Antihistamine
Antihistamine